Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01347736
Recruitment Status : Completed
First Posted : May 4, 2011
Last Update Posted : April 4, 2018
Information provided by (Responsible Party):
Mayo Clinic

Brief Summary:
This pilot clinical trial studies how well scrambler therapy works treating chronic pain in patients with rash from varicella zoster virus infection. Scrambler therapy may help relieve pain from a rash caused by varicella zoster virus infection

Condition or disease Intervention/treatment Phase
Dermatologic Complications Pain Viral Infection Other: scrambler therapy Other: questionnaire administration Procedure: dermatologic complications management/prevention Not Applicable

Detailed Description:


I. To explore whether we can decrease post-herpetic neuralgia (PHN) pain with scrambler therapy.

OUTLINE: Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity. After the completion of study treatment, patients are followed up for 10 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Scrambler Therapy for the Treatment of Chronic Zoster Pain
Actual Study Start Date : March 2011
Actual Primary Completion Date : November 7, 2012
Actual Study Completion Date : November 7, 2014

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Shingles

Arm Intervention/treatment
Experimental: Treatment (pain therapy)
Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
Other: scrambler therapy
Undergo scrambler therapy

Other: questionnaire administration
Ancillary studies

Procedure: dermatologic complications management/prevention
Undergo scrambler therapy
Other Names:
  • complications management/prevention, dermatologic
  • management/prevention, dermatologic complications

Primary Outcome Measures :
  1. Change in pain on a 0-10 numerical rating scale. [ Time Frame: 10 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pain of >= 1 month (30 days) duration attributed to zoster, for which the patient wants intervention
  • Pain at least a four out of ten problem during the prior week, on a 0-10 scale where zero was no problem and ten was the worst possible problem
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 0, 1, or 2
  • Life expectancy >= 3 months (90 days)
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Provide informed written consent

Exclusion Criteria:

  • Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown
  • Pregnant women
  • Patients with implantable drug delivery systems, e.g. Medtronic Synchromed
  • Patients with heart stents or metal implants such as pacemakers, automatic defibrillators, aneurysm clips, vena cava clips and skull plates; (metal implants for orthopedic repair, e.g. pins, clips, plates, cages, joint replacements are allowed as are central venous access devices)
  • Patients with a history of myocardial infarction or ischemic heart disease within the past six months
  • Patients with history of epilepsy, brain damage, use of anti-convulsants for seizure prevention, symptomatic brain metastases; Note: anti-convulsant use is allowed for neuropathy and heart failure (HF) if on a stable dose
  • Other identified causes of pain in the area that was affected by herpes zoster
  • Skin conditions such as open sores that would prevent proper application of the electrodes
  • Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study
  • Prior treatment with Calmare MC-5A therapy
  • Patient initiation of a new analgesic treatment within 7 days prior to initiation of protocol treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01347736

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Charles Loprinzi Mayo Clinic
Layout table for additonal information
Responsible Party: Mayo Clinic Identifier: NCT01347736    
Other Study ID Numbers: MC10CE
NCI-2011-00338 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
MC10CE ( Other Identifier: Mayo Clinic Cancer Center )
11-00531 ( Other Identifier: Mayo Clinic IRB )
NCI-2011-00338 ( Registry Identifier: NCI CTRP )
First Posted: May 4, 2011    Key Record Dates
Last Update Posted: April 4, 2018
Last Verified: February 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases